News - Merck Serono, Regulation

Filter

Current filters:

Merck SeronoRegulation

Popular Filters

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux

24-12-2013

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Briefs: Takeda and Lundbeck file vortioxetine NDA; Merck Serono spin-out

03-10-2012

Japan's biggest drugmaker Takeda Pharmaceutical (TYO: 4502) and partner Danish CNS specialist Lundbeck…

AsceneurionBiotechnologyLundbeckMerck KGaAMerck SeronoMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvortioxetine

News briefs from Threshold, Merck KGaA and GSK

18-09-2012

US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial…

BiotechnologyErbituxEuropeGlaxoSmithKlineMerck KGaAMerck SeronoOncologyPharmaceuticalRegulationResearchSynflorixTH-302Threshold PharmaceuticalsVaccines

Expanded use for Merck Serono’s Rebif in EU

25-01-2012

Merck Serono, the Switzerland-based division of Germany’s Merck KGaA (MRK: DE), says that that the…

EuropeMerck KGaAMerck SeronoNeurologicalPharmaceuticalRebifRegulation

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis

25-11-2011

In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top